The pancreas has four main types of endocrine cells. The first one of them is alpha cells, which synthesize glucagon, the second one is beta cells, which synthesize insulin, the third one is delta cells, which synthesize somatostatin, the fourth one is pancreatic polypeptide (PP) cells, which synthesize pancreatic polypeptide (1-3), and the fifth type is ghrelin cells, which synthesize ghrelin in mammalian pancreatic islet cells (4,5). Ghrelin cells are the most important source of ghrelin in the fetal period (6). Their number increases during this period, and these cells are located around pancreatic islands (4,5). It has been shown that when the number of beta cells decreases, the number of ghrelin cells increases in experimental mouse models (5). Ghrelin controls glucose metabolism (7). Ghrelin levels decrease in type 2 diabetes individuals and healthy offspring of them (8-10). There is a relationship between ghrelin and insulin levels. The authors demonstrated that insulin plays an important role in inhibition of nutrition-related ghrelin as a modulating factor. 

INTRODUCTION

The pancreas has four main types of endocrine cells. The first one of them is alpha cells, which synthesize glucagon, the second one is beta cells, which synthesize insulin, the third one is delta cells, which synthesize somatostatin, the fourth one is pancreatic polypeptide (PP) cells, which synthesize pancreatic polypeptide (1-3), and the fifth type is ghrelin cells, which synthesize ghrelin in mammalian pancreatic islet cells (4,5). Ghrelin cells are the most important source of ghrelin in the fetal period (6). Their number increases during this period, and these cells are located around pancreatic islands (4,5). It has been shown that when the number of beta cells decreases, the number of ghrelin cells increases in experimental mouse models (5). Ghrelin controls glucose metabolism (7). Ghrelin levels decrease in type 2 diabetes individuals and healthy offspring of them (8-10). There is a relationship between ghrelin and insulin levels. The authors demonstrated that insulin plays an important role in inhibition of nutrition-related ghrelin as a modulating factor.
labor of plasma ghrelin (11,12). Furthermore, the hyperglycemic and lowering effect also occurred when ghrelin is given to a healthy human. These findings reveal effects of ghrelin on insulin secretion and glucose metabolism (13,14).

Diabetes mellitus is a chronic metabolic disease. Prolonged hyperglycemia causes damage to some tissues, such as kidney tissue, and an increase in oxidative stress. This situation induces renal damage. Therefore, kidney damage is associated with increased oxidative stress (15). Renal failures are the cause of diabetic nephropathy. One of the mortalities caused in patients who have insulin-dependent and non-insulin-dependent diabetes is renal disease (16). Diabetic nephropathy is a major problem in diabetic patients (17). Reactive oxygen species (ROS) has an important role in diabetic pathogenesis (18). Antioxidants protect cells and tissues from oxidative damage (19). The kidney damage caused by oxidative stress is reduced by increased antioxidant levels. Ghrelin may be an important antioxidant agent with increasing antioxidant enzyme activities (20,21). Increased ROS levels and decreased antioxidant levels are observed in diabetes (22). Then, free radicals come into play, and this situation occurs with nonenzymatic glycation of proteins, oxidation of glucose, increase of lipid peroxidation (LPO), and the development of insulin resistance (23). Oxidative stress emerges from an imbalance between the formed radicals and the level of antioxidants. It has been shown in many studies that complications that occur in diabetes cause the development of oxidative stress (18,24,25). Ghrelin has an antioxidant effect and is a strong lipolytic hormone (26). Fujimura et al. demonstrated that ghrelin has a significant role in the decrease of ROS levels in angiotensin II-induced renal damage in mice (27).

In the present study, it was purposed to reveal the anti-proliferative and antioxidants effects of ghrelin microscopically and biochemically in the kidney of newborn normal and STZ-induced diabetic rats following exogenous administration of ghrelin.

**MATERIAL AND METHODS**

**Animals**

The Local Ethics Committee on Animal Research of Istanbul University approved for all the experimental procedures. In this study, newborn Wistar albino female and male rats were divided into four groups (n=5 per group, totally 20 rats in histological and immunohistochemical assays; n=13 for control and ghrelin control groups, n=9 for diabetic and diabetic group given ghrelin, totally 44 rats in biochemical assays). In the first group, which was the control group, physiological saline was given intraperitoneally for four weeks. Ghrelin (AnaSpec, Fremont, CA, USA, 24160) was given subcutaneously as 100 μg/kg/day from the third day to the fourth week to the second group rats. In the third group, which was the diabetic group, were treated with a single dose of 100 mg/kg streptozotocin (STZ) on the second day after birth to induce newborn diabetes, intraperitoneally. Ghrelin after STZ injection was given to the rats in the last group. At the end of the experiment, the rats were sacrificed. Their blood samples were taken for biochemical analysis, and kidney tissues were taken for examining microscopical and biochemical parameters.

**Histological and Immunohistochemical Assays**

Kidney tissues fixed in Bouin’s solution for 24 hours at room temperature were used. After the series of ethanol and xylene for dehydration and cleaning, the kidney tissues were embedded in paraffin. The embedded kidney tissues were cut as a 5 μm section for a histological assay and a 4 μm section for an immunohistochemical assay. The kidney tissues were stained with a Periodic Acid Schiff reagent for microscopy analysis. The poly-L-lysine was used to coat microscope slides. The sections were placed on these slides for the immunohistochemical assay. Caspase-3 and proliferating cell nuclear antigen (PCNA) were investigated for immunohistochemical assay. The paraffin was removed by keeping the sections in toluene. After this stage, the sections were incubated with hydrogen peroxide (3%) to block the endogenous peroxidase activity. The Histostain Plus Broad Spectrum Kit (Zymed, 85-9743, South San Francisco, CA), PCNA antibody (Ab-1 MS-106-P, Neomarkers, Fremont, CA, dilution 1:50, 30 minutes at room temperature), and caspase-3 (Millipore AB3623, Bedford, MA, USA; dilution 1:50, overnight at +4°C) were utilized for immunohistochemical labeling by employing the streptavidin-biotin-peroxidase technique. The 3-amin-9-ethyl carbazole was used to detect of immunoreactivity. Mayer’s hematoxylin was used for counterstain of the sections and mounted using glycerol vinyl alcohol mounting medium.

Histological and immunohistochemical assays were conducted by using an X40 objective and X10 ocular system of the Olympus CX-45 microscope as Microscopic analysis. The results were explained by the histological score with a grade from 0 to 3 as negative (0), weak (1), moderate (2), and strong (3). PCNA immunopositive cells were counted for each slide at a minimum of ten random fields.

**Biochemical Assays**

In the previous study, blood glucose levels were measured, and Turk et al. decided that the rats were diabetic (28). Creatinine, uric acid, and serum urea levels were investigated by the methods of Jaffe reaction (29), Caraway (30), and acetylmethylxime (31), respectively. Cold 0.9% NaCl and glass equipment were used for homogenization of kidney tissues. 10% (w/v) homogenate was obtained. It was centrifuged. Clear supernatants were utilized for protein, glutathione (GSH), and LPO levels and antioxidant enzyme analysis. GSH levels were determined in accordance with the Beutler method using Ellman’s reagent (32). LPO levels were investigated by Ledwozyw’s method in kidney homogenates (33). Catalase (CAT) activity was determined in accordance with Aebi (34), superoxide dismutase (SOD) activity in accordance with Mylroie's method (35), myeloperoxidase (MPO) activity in accordance with Wei and Frenkel (36), and xanthine oxidase (XO) activity in accordance with Corte and Stirpe with a number of modifications (37). The protein level was determined by employing the method of Lowry in the supernatants. The bovine serum albumin was used as standard for this method (38).
Statistical Analysis
The Mann-Whitney U tests and the two-way ANOVA using GraphPad Prism version 4.0 computer package were used for analysis of the histological and immunohistochemical data. The unpaired Student’s t-test and one-way ANOVA using the NCSS statistical computer package were used for the biochemical results. The results were presented as mean±SE for histological and immunohistochemical assays; as mean±SD for biochemical assays. P values less than 0.05 were considered significant.

RESULTS
Histological and Immunohistochemical Assays
Degenerative changes such as expansion in the capsular spaces of glomeruli, ruptures at the brush border in apical, desquamated nuclei and cytoplasmic debris in the lumen of proximal tubules, necrotic areas, moderate cytoplasmic vacuolar degeneration, and hyperemia in the kidney tissue of rats given STZ were determined. These changes were not changed in the kidney tissue of the diabetic animals given ghrelin (Figure 1).

Biochemical Assays
The serum uric acid and urea levels in the diabetic group were determined to have increased significantly in comparison with the control group (p<0.001; p<0.05). Ghrelin caused a significant decrease in creatinine, uric acid, and urea levels in the diabetic group (p<0.0001; p<0.001; p<0.05) (Table 1).

Table 1. Serum urea, creatinine and uric acid levels of all groups

| Group               | Urea (mg/dL)*       | Creatinine (mg/dL)* | Uric Acid (mg/L)* |
|---------------------|---------------------|---------------------|-------------------|
| Control             | 59.84±7.48          | 1.32±0.15           | 4.23±0.22         |
| Control+Ghrelin     | 76.19±26.14         | 0.65±0.23           | 3.39±0.67         |
| Diabetic            | 106.41±20.41        | 1.42±0.02           | 5.14±0.39         |
| Diabetic+Ghrelin    | 72.79±5.84          | 0.51±0.03           | 3.20±0.67         |
| P\textsubscript{ANOVA} | 0.041              | 0.0001              | 0.0001            |

*Mean±SD; 'p<0.05 versus control group, "p<0.05 versus diabetic group, 'p<0.0001 versus control group, "p>0.05 versus control group, "p<0.0001 versus diabetic group, 'p<0.001 versus control group and "p<0.001 versus diabetic group.

Figure 1. A normal histological appearance was observed in the kidney tissue of the control (1), control group given ghrelin (2), STZ group (3), diabetic group given ghrelin (4). G: Glomeruli, P: Proximal tubules, D: Distal tubules, N: Necrotic area, V: Vacuolar degeneration, ↔: Ruptures at the brush border in apical, •: Cytoplasmic debris and ▶: Desquamated nuclei in the lumen of proximal tubules, ↔: Expansion in capsular spaces of glomeruli. Periodic Acid Schiff (PAS) staining technique. 400x magnification

Figure 2. A) PCNA immune+ cells (●) are observed with immunohistochemistry in kidney tissue of the control group (1), control group given ghrelin (2), STZ group (3), diabetic group given ghrelin (4). G: Glomeruli, P: Proximal tubules, D: Distal tubules. B) PCNA immune+ cell number for all groups. 'p<0.05 versus control group, "p<0.01 versus ghrelin group, "p<0.05 versus ghrelin group, 'p<0.05 versus diabetic group. 400x magnification
A significant reduction in GSH levels was determined in the diabetic group in comparison with the control groups (p<0.0001). Ghrelin administered to the diabetic rats induced a significant increase in GSH levels in the kidney (p<0.0001). LPO levels increased significantly in the diabetic rats compared to the control groups (p<0.001). There was a decrease in LPO levels in the kidney with given ghrelin to STZ-diabetic rats (p<0.001) (Table 2).

A significant reduction in kidney CAT and SOD activities were determined in the diabetic group, compared to the control groups (p<0.001). Kidney with given ghrelin to STZ-diabetic rats (p<0.001) (Table 2). There was a decrease in LPO levels in the kidney of ghrelin-administrated diabetic rats (p<0.001) (Table 2).

### Table 2. Kidney glutathione (GSH) and lipid peroxidation (LPO) levels of all groups

| Group          | GSH (nmol GSH/mg protein)* | LPO (nmol MDA/mg protein)* |
|----------------|---------------------------|----------------------------|
| Control        | 10.46±3.56                | 0.39±0.03                  |
| Control+Ghrelin| 9.64±2.63                 | 0.41±0.04                  |
| Diabetic       | 2.73±1.15                 | 0.65±0.05                  |
| Diabetic+Ghrelin| 11.31±2.21               | 0.37±0.07                  |
| PANOVA         |                           | 0.0001                     |

*Mean ± SD; *p<0.0001 versus control group, *p<0.001 versus diabetic group, *p<0.001 versus control group and *p<0.001 versus diabetic group.

A significant reduction in kidney CAT and SOD activities were determined in the diabetic group in comparison with the control groups (p<0.0001). However, MPO and XO activities significantly increased in the diabetic group compared to the control group (p<0.001; p<0.05) (Table 3). The exogenously administered ghrelin induced an increase in kidney CAT and SOD activities (p<0.001; p<0.005), and a decrease in kidney MPO and XO activities in the diabetic rats (p<0.05; p<0.0001) (Table 3).

### Table 3. Kidney catalase (CAT), superoxide dismutase (SOD), myeloperoxidase (MPO) and xanthine oxidase (XO) activities of all groups

| Group          | CAT (U/mg protein)* | SOD (U/g protein)* | MPO (U/g tissue)* | XO (U/g protein) |
|----------------|---------------------|--------------------|-------------------|------------------|
| Control        | 291.45±41.44        | 15.05±4.57         | 41.57±15.87       | 1.89±0.67        |
| Control+Ghrelin| 218.32±86.91        | 11.60±4.84         | 44.07±11.91       | 1.31±0.82        |
| Diabetic       | 211.83±36.69        | 7.47±0.88          | 83.10±14.84       | 2.60±0.28        |
| Diabetic+Ghrelin| 269.01±88.22       | 9.66±1.41          | 38.03±14.63       | 1.73±0.19        |
| PANOVA         | 0.003               | 0.001              | 0.001             | 0.001            |

*Mean ± SD; *p<0.05 versus control group, *p<0.0001 versus control group, *p<0.001 versus diabetic group, *p<0.001 versus diabetic group, *p<0.001 versus control group, *p<0.05 versus diabetic group and *p<0.0001 versus diabetic group.

**DISCUSSION**

The blood glucose levels decreased in diabetic rats given ghrelin compared to non-treated diabetic rats (28). Ghrelin administration inhibits the diabetic effects as a result of reducing the blood glucose levels in newborn diabetic rats. Brouwers et al. showed that kidney damage occurred as a result of administering 250 mg/kg STZ doze to mice (39). They have observed disruption of the brush border, the loss of nucleus in proximal tubule cells, dilatation of non-proximal tubules, and moderate acute tubular injury. Koyuturk et al. found that ghrelin reduced cell proliferation and caspase 8 activity, while caspase-3 activity did not change in the liver tissue of ghrelin-administrated diabetic rats (40). Renal damage caused by ischemia/reperfusion or cisplatin showed that ghrelin administration reduced apoptosis (41,42). In the present study, some degenerative changes in the STZ treated kidney tissue of newborn rats were determined. Ghrelin did not reverse these changes in diabetic animals. Ghrelin did not affect the renal injury of experimental diabetic rats microscopically. However, PCNA immune+ cell number decreased with the administration of ghrelin in diabetic rats. Proximal tubule epithelial cells start to proliferate to prevent acute injury (43,44). Proliferation increases in the proximal tubule after injury. Therefore, the occurred cell number decrease by cell death is compensated (45). Danilewicz and Wagrowska-Danilewicz suggest that cell proliferation was inhibited by ghrelin in control kidney tissues and non-proliferative glomerulopathies. The lack or low level of this protein in proliferative glomerulopathies was observed (46). It was thought that when the cells were damaged, it increased the number of cells to prevent damage. Therefore, PCNA immune+ cell number increased in the diabetic group. It decreased because of reduced damage with the administration of ghrelin.

Necrotic areas in the kidney tissue of the experimental group were determined by histochemical staining, and it was desired to investigate caspase-3 activity to determine apoptosis, a form of cell death. There were no changes in caspase-3 between the four groups. We thought that cell death might occur in the diabetic group. However, apoptotic cell death did not occur with the administration of STZ, statistically.

Creatinine levels decreased with the administration of ghrelin in renal damage caused by cisplatin (42). In another study, creatinine levels were shown to be higher compared to the control group in diabetic nephropathy (47,48). Van Ginhuizen et al. have shown that urea levels increased after reperfusion (49). However, there were no changes between both the control group and the group given ghrelin. Furthermore, uric acid, urea, and creatinine levels increased in an experimental model of diabetic nephropathy compared to the control group (50). In our study, uric acid, creatinine, and serum urea levels reduced in the diabetic group given ghrelin. It can be said that ghrelin takes a significant part in the prevention of renal damage.
Ghrelin increases antioxidant activity. Therefore, it has antioxidant properties in the rat kidney tissue (51). The authors indicated that SOD and GSH levels reduced in the kidney tissue in the diabetic group compared to the control group (52). In another similar study, CAT, SOD activities and GSH levels reduced, while malondialdehyde levels increased in diabetic nephropathy in comparison with the control group (50). Sudhakara et al., have shown that LPO and XO levels increased in the kidney tissue of diabetic rats (53). Sacan et al., has shown that LPO, CAT, SOD, MPO, and XO significantly increased, while GSH levels reduced in lung tissues in diabetic rats in comparison with the control group (54). In our study, kidney GSH level, SOD, and CAT activities significantly increased, while XO and MPO activities and LPO level significantly reduced in the diabetic group given ghrelin. Ghrelin reversed biochemical changes in diabetic rats.

CONCLUSION

The biochemical results showed that ghrelin provides recovery of complications in kidney tissue in newborn diabetic rats. Ghrelin treatment partially reversed the renal injury of experimental diabetic rats because of the antioxidant properties of ghrelin.

Peer-review: Externally peer-reviewed.

Author Contributions: Conception/Design of study: S.B., N.O.; Data Acquisition: A.K.K., O.S., R.Y.; Data Analysis/Interpretation: A.K.K., O.S., R.Y.; Drafting Manuscript: A.K.K.; Critical Revision of Manuscript: A.K.K., O.S., S.B., R.Y., S.B.; Final Approval and Accountability: A.K.K., O.S., S.B., R.Y., S.B.; Technical or Material Support: S.B., O.S., R.Y., S.B.; Supervision: S.B.

Conflict of Interest: The authors declare that they have no conflicts of interest to disclose.

Financial Disclosure: This work was supported by Scientific Research Project Coordination Unit of Istanbul University. Project No. BYP-36942.

REFERENCES

1. Edlund H. Developmental biology of the pancreas. Diabetes 2001; 50(Suppl 1): S5-S9.
2. Brissova M, Fowler MJ, Nicholson WE, Chu A, Hirshberg B, Harlan DM, et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 2005; 53: 1087-97.
3. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 2006; 103: 2334-9.
4. Wierup N, Svensson H, Mulder H, Sundler F. The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept 2002; 107: 63-9.
5. Prado CL, Pugh-Bernard AE, Elghazi L, Sosa-Pineda B, Sussel L. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc Natl Acad Sci USA 2004; 101: 2924-9.
6. Chanoine JP, Wong AC. Ghrelin gene expression is markedly higher in foetal pancreas compared with foetal stomach: effect of maternal fasting. Endocrinology 2004; 145: 3813-20.
7. O. Ukkola, Ghrelin and metabolic disorders. Curr Protein Pept Sc 2009; 10: 1-27.
8. Ostergard T, Hansen TK, Nyholm B, Gravholt CH, Djurhuus CB, Hossoda H, et al. Circulating ghrelin concentrations are reduced in healthy offspring of type 2 diabetic subjects, and are increased in women independent of a family history of type 2 diabetes. Diabetologia 2003; 46:1: 134-6.
9. Poykko SM, Kellokoski E, Horkkoe S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52:10: 2546-53.
10. Barazzoni R, Zanetti M, Ferreira C, Vinci P, Pirulli A, Mucci M, et al. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3935-40.
11. McCowen KC, Maykel JA, Bistrian BR, Ling PR. Circulating ghrelin concentrations are lowered by intravenous glucose or hyperinsulinemic euglycemic conditions in rodents. J Endocrinol 2002; 175: R7-R11.
12. Saad MF, Bernaba B, Huw CM, Jinagouda S, Fahmi S, Kogosov E, et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 2002; 87: 3997-4000.
13. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86: 5083-6.
14. Broglio F, Gottero C, Prodham F, Gauna C, Muccioli G, Papotti M, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004; 89: 3062-5.
15. Nasri H, eian-Kopaei MR. Protective effects of herbal antioxidants on diabetic kidney disease. J Res Med Sci 2014; 82-3.
16. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-9.
17. Winograd AI. Banting lecture 1986. Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987; 36(3): 396-406.
18. Baynes, J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
19. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982; 47(5): 412-26.
20. Obay BD, Tasdemir E, Tumer C, Bilgin H, Atmaca M. Dose dependent effects of ghrelin on pentyleneetetrazole-induced oxidative stress in a rat seizure model. Peptides 2008; 29: 448-55.
21. Zwirska-Korczala K, Adamczyk-Sowa M, Sowa P, Pilec K, Suchane K, Pierzchala K, et al. Role of leptin, ghrelin, angiotensin II and orexins in STZ L1 preadipocyte cells proliferation and oxidative metabolism. J Physiol Pharmacol 2007; 58: 53-64.
22. Wiernsperger NF. Oxidative stress as a therapeutic target in diabetics: revisiting the controversy. Diabetes Metab 2003; 29: 579-85.
23. Maritim AC, Sanders RA, Watkins III JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17: 24-38.
24. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2009; 52: 562-71.
25. Aslam F, Iqbal S, Nasir M, Anjum AA. White sesame seed oil mitigates blood glucose level, reduces oxidative stress, and improves biomarkers of hepatic and renal function in participants with type 2 diabetes mellitus. J Am Coll Nutr 2018; 27: 1-12.
26. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin: a hormone with multiple functions. Front Neuroendocrinol 2004; 25(1): 27-68.

27. Fujimura K, Wakino S, Minakuchi H, Hasegawa K, Hosoya K, Komatsu M et al. Ghrelin protects against renal damages induced by angiotensin-II via an antioxidative stress mechanism in mice. PLoS One 2014; 9(4): e94373.

28. Turk N, Dagistanli FK, Sacan O, Yanardag R, Bolkent S. Obestatin and insulin in pancreas of newborn diabetic rats treated with exogenous ghrelin. Acta Histochem 2012; 114(4): 349-57.

29. Caraway WT. Determination of uric acid in serum by a carbonate method. Am J Clin Pathol 1955; 25(1): 840-5.

30. Barker SB. The direct colorimetric determination of urea in blood and urine. J Biol Chem 1944; 152: 453-63.

31. Beutler E. Glutathione in red cell metabolism. In: A Manual of Biochemical Methods. New York: Grune and Stratton 1975; pp. 112-4.

32. Liu Y, Liu J, Liao G, Zhang J, Chen Y, Li L, et al. Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. Nephrology 2010; 30(6): 633-8.

33. Caraway WT. Determination of uric acid in serum by a carbonate method. Am J Clin Pathol 1955; 25(1): 840-5.

34. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-6.

35. Mylorie AA, Collins H, Umbles C, Kyle J. Erythrocyte superoxide dismutase activity and other parameters of copper status in rats ingesting lead acetate. Toxicol Appl Pharmacol 1986; 82: 512-20.

36. Wei H, Frenkel K. In vivo formation of oxidized DNA bases in tumor promoter-treated mouse skin. Cancer Res 1991; 51(16): 4443-9.

37. Corte ED, Stripe F. Regulation of xanthine oxidase in rat liver: Modifications of the enzyme activity of rat liver supernatant on storage at 20 degrees. Biochem J 1968; 108: 349-51.

38. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.

39. Nishimatsu H, Suzuki E, Satonaka H, Nagata D, Oba S, et al. Ghrelin improves renal function in mice with ischemic acute renal failure. J Am Soc Nephrol 2006; 17(1): 113-21.

40. Nojiri T, Hosoda H, Kimura T, Tokudome T, Miura K, Takabatake H, et al. Protective effects of ghrelin on cisplatin-induced nephrotoxicity in mice. Peptides 2016; 82: 85-91.

41. Witzgall R, Brown D, Schwarz C, Bonventre JV. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 1994; 93: 2175-88.

42. Guo JK, Cantley LG. Cellular maintenance and repair of the kidney. Annu Rev Physiol 2010; 72: 357-76.

43. Cuppage FE, Neagoy DR, Tate A. Repair of the nephron following temporary occlusion of the renal pedicle. Lab Invest 1967; 17: 660-74.

44. Elsherbiny NM, Zaitone SA, Mohammad HMF, El-Sherbiny M. Renoprotective effect of nifoxazide in diabetes-induced nephropathy: impact on NFκB, oxidative stress, and apoptosis. Toxicol Mech Method 2018; 28-6: 467-473.

45. Sudhakara G, Ramesh B, Mallalah P, Sreenivasulu N, Saralakumari D. Protective effect of ethanolic extract of Commiphora mukul gum resin against oxidative stress in the brain of streptozotocin induced diabetic Wistar male rats. Excli J 2012; 11: 576-92.

46. Sacan O, Turkyilmaz IB, Bayrak BB, Mutlu O, Akev N, Yanardag R. Zinc supplementation ameliorates glycoprotein components and oxidative stress changes in the lung of streptozotocin diabetic rats. Biometals 2016; 29(2): 239-48.